» Articles » PMID: 19793629

Bronchopulmonary Dysplasia: Definitions and Long-term Respiratory Outcome

Overview
Journal Early Hum Dev
Publisher Elsevier
Date 2009 Oct 2
PMID 19793629
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease that develops as a consequence of perinatal/neonatal lung injury, and it is one of the most important sequelae of premature birth. In this article we discuss recent changes in the definition of BPD, the main differences between the old and the new form and we summarize recent data on long-term respiratory outcome. The diagnosis of BPD is currently based on the need for supplemental oxygen for at least 28 days after birth, and its severity is graded according to the respiratory support required at 36 postmenstrual weeks. The "new BPD" is mainly a developmental disorder in which the immature lung fails to reach its full structural complexity. Longitudinal studies on children with BPD identified, at all ages, a greater need to use inhaled asthma medication and a significant airflow obstruction. Whether survivors of BPD and prematurity have a risk of developing a COPD-like phenotype with aging is a question that only lung function studies extended to middle-age and beyond will answer.

Citing Articles

Kidney complications in children with bronchopulmonary dysplasia.

Wallace S, Geers E, Niehaus J, Cristea A, Starr M Pediatr Res. 2024; .

PMID: 39443697 DOI: 10.1038/s41390-024-03638-x.


Lung ultrasound in early prediction of bronchopulmonary dysplasia in pre-term babies.

Abdelrazek A, Kamel S, Elbakry A, Elmazzahy E J Ultrasound. 2024; 27(3):653-662.

PMID: 38907789 PMC: 11333650. DOI: 10.1007/s40477-024-00913-9.


Premature infants born <28 weeks with acute kidney injury have increased bronchopulmonary dysplasia rates.

Starr M, Schmicker R, Halloran B, Heagerty P, Brophy P, Goldstein S Pediatr Res. 2023; 94(2):676-682.

PMID: 36759749 PMC: 10403374. DOI: 10.1038/s41390-023-02514-4.


Anakinra Pilot - a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants.

Green E, Metz D, Galinsky R, Atkinson R, Skuza E, Clark M Front Immunol. 2022; 13:1022104.

PMID: 36389766 PMC: 9647081. DOI: 10.3389/fimmu.2022.1022104.


CPAP-induced airway hyper-reactivity in mice is modulated by hyaluronan synthase-3.

Mayer C, Ganguly A, Mayer A, Pabelick C, Prakash Y, Hascall V Pediatr Res. 2021; 92(3):685-693.

PMID: 34750521 PMC: 9079185. DOI: 10.1038/s41390-021-01695-0.